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Abstract
Purpose Plant sterols (PS) are well known for their low-
density lipoprotein cholesterol-lowering effect. Until
recently, they were believed to have little or no impact on
blood triglycerides (TG). However, studies taken individ-
ually were possibly lacking statistical power to detect
modest TG decreases. This study was performed to quan-
tify the TG-lowering effect of PS by pooling individual
subject data from 12 randomised controlled trials that
investigated the effects of PS on blood lipids.
Methods The main outcome variable was the control-
adjusted PS effect on relative (%) and absolute (mmol/L)
changes in TG. The relative and absolute changes in high-
density lipoprotein cholesterol (HDL-C) were also asses-
sed. Differences in changes of serum lipid concentrations
between PS and control treatments were estimated by an
ANCOVA using a random effect model which included PS
intake (active or control), study and predefined subject
characteristics.
Results The twelve randomised controlled trials included
in total 935 hypercholesterolaemic subjects not preselected
based on their baseline TG concentrations. In most studies,
the PS dose ranged between 1.6 and 2.5 g/day. PS intake
significantly lowered serum TG by 6.0% (95% CI: -10.7,
-1.2) or 0.12 mmol/L (95% CI: -0.20, -0.04). No sig-
nificant interaction was observed between PS intake and
baseline TG concentrations on relative changes, but, on
absolute changes, interaction was significant with larger TG
decreases observed with higher TG concentrations at base-
line. No effects were observed on HDL-C concentrations.
Conclusions These results show that PS exert a modest
TG-lowering effect which is dependent on baseline
concentrations.
Keywords Plant sterols  Triglycerides  Cholesterol 
Pooled analysis  Diet and lifestyle
Introduction
Plant sterols (PS) and stanols, their saturated counterparts,
are well known for their total and low-density lipoprotein
cholesterol (LDL-C)-lowering effect. To date, several
meta-analyses have summarised and quantified the LDL-
C-lowering effect of PS/stanol-enriched foods and their
dose–response relationship [1–4]. Possibly due to the fact
that the large number of human intervention studies with
PS/stanols were designed and powered to detect a signifi-
cant effect on LDL-C, in most studies taken individually,
the effect of PS/stanols on serum triglycerides (TG) was
not estimated or not detected. However, significant reduc-
tions in TG concentrations after PS intervention have
incidentally been observed [5–8]. Furthermore, a recent
meta-analysis of individual subject data from five studies,
which aimed at studying the relationship between subjects’
baseline characteristics and the effects of plant stanol-
enriched spreads on serum lipid concentrations, indicated
that plant stanols not only lower serum concentrations of
LDL-C, but also TG concentrations [9]. More recently,
large TG reductions were observed in metabolic syndrome
patients consuming PS/stanol-enriched foods [10, 11].
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Elevated TG concentrations are increasingly being
recognised as a possible independent risk factor for coro-
nary heart disease (CHD), and TG-lowering therapy next to
lowering LDL-C may be considered relevant especially
in high-risk populations such as, e.g., subjects with
dyslipidaemia as characterised in the metabolic syndrome
[12–14].
In the recent meta-analysis that indicated a TG-low-
ering effect of plant stanols [9], significant interaction
was observed between baseline TG concentrations and
plant stanol intake, resulting in larger TG reductions
(expressed in mmol/L) with higher baseline TG concen-
trations. Even when expressed in terms of relative
(expressed in %) changes from baseline, TG reductions
were more pronounced when baseline TG concentrations
were higher. For investigating the TG-lowering effect of
PS, having individual subject data would thus allow
making better adjustments for baseline TG concentra-
tions resulting in more precise estimations. As such, the
aim of the present study was to quantitatively evaluate
the TG-lowering effect of PS by pooling individual
subject data from randomised controlled trials that
were made available by investigators from independent
research groups.
In order to specifically take into account the baseline
TG concentrations in the estimation of the TG-lowering
effect, the main outcome was expressed as the relative
change in TG from baseline values. In addition, and for
better understanding the impact of baseline concentrations
on the observed reductions in TG, the absolute changes
were calculated. As HDL-C metabolism is closely related
to that of TG via the action of the cholesterol-ester
transfer protein (CETP) [15], the effect of PS-enriched
food consumption on HDL-C concentrations was also
evaluated.
Methods
Selection of the studies
Data sets of 14 Unilever-sponsored PS intervention studies
published in 12 publications were made available by
different independent research groups [5, 16–26] that
published their findings in peer-reviewed journals. Studies
were eligible for the current pooled analysis if they were
randomised placebo-controlled trials with human adults not
preselected based on their baseline TG concentrations,
had used the ‘usual’ plant sterols (4-desmethylsterols),
had disposal of TG data at baseline and at end of inter-
vention as well as relevant co-variable data, and had no
co-intervention from which the effect of PS could not be
isolated.
Ferulated PS as found, e.g., in rice bran oil were
excluded because these are not commonly used for food/
supplement enrichment. In addition, there is no consensus
on their cholesterol-lowering effect [16, 27]; thus, their
potential impact on serum TG and/or HDL-C may also be
different from that of other PS. Because the cholesterol-
lowering effect of plant sterols is additive to that of statins
[17, 28] and dietary fat modifications (diets low in total fat,
saturated fat, and cholesterol content or high in vegetable
oil) [29–31], we assumed that a similar additive effect
could be expected in case of an impact on serum TG and
HDL-C. Therefore, studies that prescribed statins or dietary
fat modifications in both the control and the treatment
group/phase within each study were included in the present
analysis.
Eligibility for inclusion in the pooled analysis was judged
by evaluating the full publication, the study protocol and the
data set. Out of the 14 studies, one study was excluded
because it did not measure TG concentrations [18] and
another because initial lipid values were not readily avail-
able [19]. One study [23] consisted of two parallel arms with
a randomised controlled cross-over design within each arm;
these parallel arms were considered as two separate cross-
over studies. In another study [24], 2 separate cross-over
trials were described. Thus, individual subject data from a
total of 12 studies from 10 publications that met the selec-
tion criteria were available for inclusion in the current
pooled analysis [5, 16, 17, 20–26].
Data extraction and quality assessment
For each subject, the following data were extracted from
the different data sets: study identification, gender, BMI,
age, treatment (active or control), and TG and HDL-C data
at baseline and at end of intervention. When the lipids were
measured at various time points during the intervention, the
values corresponding to or closest to the 4-week time point
were taken for the analysis. If measurements were done on
two different days at the end of the intervention, the mean
value of those two measurements was taken.
Study quality was assessed as previously reported [3]
using a custom-designed tool adapted from the Delphi
Consensus [32] and the method by Chalmers et al. [33].
However, due to a lack of consensus on which scoring
system is the best and hence scoring is intrinsically sub-
jective [34], quality scores were not used to exclude lower
quality trials or to weigh the data accordingly.
Statistical analysis
The primary outcome variables were the control-adjusted
relative (%) and absolute (mmol/L) changes from baseline
in TG due to the PS treatment. The secondary outcome
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variables were defined as the control-adjusted relative and
absolute changes from baseline in HDL-C. The relative
changes in serum TG and HDL-C were calculated as fol-
lows for each subject:
Relative change ¼ 100
 Lipid concentrationend of intervenion  Lipid concentrationstart of intervention
Lipid concentrationstartofintervention
:
Baseline lipid concentrations were defined as the lipid
concentrations at the start of the intervention phase (end of
run-in when a run-in phase was present). For cross-over
trials in which start-of-intervention measurements were not
available (n = 1), the lipid concentrations at screening
were used as baseline concentrations.
In order to standardise the variability structure of all
data in the overall pooled analysis, we only used the data
from the first study phase of cross-over studies, so that all
studies were treated as parallel studies.
For the absolute changes, analysis was done on end-
of-intervention serum lipid concentrations while adjusting
for baseline concentrations. Differences in mean relative
changes and absolute serum TG and HDL-C concentrations
between the PS group and the control group were deter-
mined by an ANCOVA using a model which initially
included PS intake (active or control), study and the pre-
defined subject characteristics age, gender, BMI and
baseline lipid concentrations and their interactions with PS
intake. Because age and gender did not significantly
(P [ 0.1) contribute to the model, the subject characteris-
tics kept in the final model were the respective baseline
lipid concentrations and BMI (and the interaction between
baseline TG concentrations and PS intake in the case of
absolute changes). The statistical analysis was performed
for the quasi intention-to-treat population [35], i.e., using
all subjects for whom end-of-intervention TG or HDL-C
values were available, and according to a random effect
model.
Sensitivity analysis was performed to determine whether
the presence of one study with patients on statins [17]
influenced the outcome. The effect of PS on TG and
HDL-C (expressed as relative change) was thus also
determined when using only the eleven studies with heal-
thy subjects. In order to verify that the use of only the first
phase of cross-over trials in the overall analysis did not
affect the outcome, a separate analysis was performed by
using all phases of the cross-over trials.
Heterogeneity between studies was assessed by calcu-
lating the Q statistic as described by DerSimonian and
Laird [36].
All analyses were performed with the statistical software
program The SAS System (SAS Version 9.2, SAS Institute,
Inc., Cary, NC, USA). ProcMixed was used to perform the
analyses.
Results
Overview of included studies and subjects
In total, 12 studies from 10 publications were available for
the current pooled analysis [5, 16, 17, 20–26]. The study by
Noakes et al. [24] included PS and plant stanol treatments;
only the data from the PS arm were used. When parallel
design studies included different PS treatments (e.g. PS
from different sources) provided in the same food format,
these strata were combined [5, 22]. In all studies, blood
lipid concentrations were measured after an overnight fast.
TG concentrations were included in the eligibility criteria
of 9 out of 12 studies and were defined as less than
3.4–4.5 mmol/L in most (n = 8) studies. Table 1 shows
the characteristics of the studies included. The majority of
studies was judged as of good quality (data not shown).
PS were esterified to vegetable oil fatty acids in all
studies except one [16] which used free PS. The food
format was margarine or spread in the majority of studies
(n = 9). In one study, a combination of spread and milk
(n = 1) was used [25], and in two studies, the vehicle for
PS was a salad dressing [23]. The PS dose varied between
0.8 and 4 g/day, with the majority of studies (n = 9)
testing doses ranging between 1.6 and 2.5 g/day. Doses of
0.8, 1.3 and 4 g/day were used in the other studies [16, 25,
26]. In most cases, PS-enriched foods were consumed for a
period of 3 weeks; in three studies, the treatment duration
was longer than 4 weeks, namely 5, 8 or 52 weeks [17, 20,
22]. In these cases, data obtained at 3 or 4 weeks were used
in order to standardise the data from all studies to a similar
point in time after the start of the intervention. Frequency
of test product intake was not reported in three studies [16,
25, 26], whereas PS were consumed 2–3 times/day with
meals in the other studies. Subjects were allowed to keep
their usual, self-selected diet during the intervention in half
of the studies [5, 16, 17, 20, 21, 25]. In the other studies,
the subjects were either provided a typical North-American
diet [23] or were advised to follow the NCEP Step 1 diet
[22, 26] or to consume a diet rich in carotenoid-rich fruits
and vegetables [24].
A total of 935 participants were included in the current
pooled analysis. In 11 of the 12 studies, the subjects were
overall healthy and were not taking any lipid-lowering
medication. The only exception was the study by Neil et al.
[17] in which subjects received statins and half of them had
familial hypercholesterolaemia. In all studies, subjects
were Caucasian. The mean age of the study populations
varied between 44 ± 12 and 58 ± 11 years. On average,
the subjects were slightly overweight (mean BMI ranging
between 24.0 ± 2.9 and 27.3 ± 3.7 kg/m2). Mean baseline
TG concentrations were on average normal to borderline
high (ranging from 1.37 ± 0.52 to 1.93 ± 1.08 mmol/L)
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according to the NCEP classification [14], whereas LDL-C
concentrations were on average above optimal to very high
(ranging from 3.15 ± 0.86 to 5.11 ± 1.07 mmol/L). The
baseline characteristics of the subjects in each of the
studies are presented in Table 1.
Heterogeneity analysis
For the relative changes in TG, there was no significant
heterogeneity between the studies as assessed by the
Q statistic (Q = 0.22, 11 degrees of freedom, P [ 0.95).
For HDL-C, no significant heterogeneity was observed
either (Q = 2.18, 11 degrees of freedom, P [ 0.95).
TG outcomes
When combining the individual subject data from all
studies, PS significantly lowered serum TG by 6.0% (95%
CI: -10.7, -1.2, P = 0.02) (Fig. 1). No significant inter-
action was observed between TG effects of PS intake and
baseline TG concentrations (P = 0.38).
When the study with statin users [17] was removed from
the analysis, the pooled estimate was a 6.3% reduction in
TG (95% CI: -11.3, -1.3, P = 0.02). An analysis of only
cross-over studies including all treatment phases showed a
similar effect, namely a 5.6% reduction in TG (95% CI:
-9.3, -2.0). The ANCOVA performed for each study
separately showed non-significant TG reductions in 8 out
of 12 studies (Fig. 1).
When the effects were expressed in absolute values, PS
intake modestly but significantly lowered TG by 0.12 mmol/L
(95% CI: -0.20, -0.04, P = 0.01). In contrast with the
results obtained when the effects were expressed relatively,
a significant (P \ 0.01) interaction between PS intake and
baseline TG concentrations was observed on absolute end-
of-intervention concentrations. In line with this finding,
larger reductions versus control were observed in subjects
with higher baseline TG concentrations (Fig. 2).
HDL-C outcomes
No significant effect of PS was observed on HDL-C; the
relative change from baseline was ?0.3% (95% CI: -1.8,
?2.5, P = 0.73) (Fig. 1). There was no interaction
between PS intake and baseline HDL-C concentrations
(P = 0.75). The removal of the study with statin users [17]
did also not have an impact (HDL-C change = ?0.5, 95%
CI: -1.8, ?2.8, P = 0.66).
Fig. 1 Forest plots. Forest plots showing the effect of plant sterols on
TG and HDL-C estimated for each of the studies included in the
overall analysis using individual subject data. The squares represent
the averages for each of the individual studies. Error bars represent
95% confidence intervals (CIs). The diamonds represent the pooled
results. The solid vertical line extending upward from zero is the null
value. In both the overall and individual study analyses, only the first
phase of cross-over trials was used. Both types of analyses were
performed using individual subject data. The overall estimate was
obtained by pooling together the individual subject data from all
studies. The same statistical model was used for the individual studies
and the overall analysis; the model included PS intake, study, age,
gender, BMI and the respective baseline concentrations and their
interactions with PS intake
Fig. 2 Impact of baseline TG concentrations. Impact of baseline TG
concentrations on the absolute (expressed in mmol/L) TG reductions
achieved with PS consumption in twelve randomised controlled trials.
In the majority of studies (n = 9), doses of 1.6–2.5 g/day were tested
(range: 0.8–4.0 g/day)
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When the analysis was performed on the absolute HDL-C
concentrations, also no significant effect of PS intake
was observed (?0.01 mmol/L; 95% CI: -0.02, ?0.04,
P = 0.54) and there was no PS intake 9 baseline HDL-C
interaction (P = 0.44).
Discussion
The present pooled analysis including individual subject
data from 12 randomised controlled trials shows that PS
intakes of around 2 g/day exert a modest TG-lowering
effect of about 6% or 0.12 mmol/L in hypercholestero-
laemic subjects not preselected based on their baseline TG
concentrations. Given the high inter-individual variation in
TG concentrations, and the fact that the individual PS
studies were primarily powered to assess the effect of PS
on LDL-C concentrations, it is likely that the absence of
statistically significant TG-lowering effects in these studies
was due to insufficient statistical power. For example, a
recent study by Mensink et al. [37] studied the serum lipid
effects of doses of plant stanols up to 9 g/day but failed to
show a significant TG reduction (e.g. *8% for 9 g/day;
P = 0.187) with only a limited number of subjects in each
of the treatment groups (*22 to 25 subjects).
The 6% TG-lowering effect observed here is consistent
with the outcome of a previous meta-analysis of individual
subject data from five studies [9] which showed a 4%
reduction in TG after 2 g/day plant stanol intake in subjects
with baseline concentrations of *2 mmol/L. These data
thus show that both PS and stanols exert a comparable
TG-lowering effect. Other recently published studies using
similar doses of PS (*2 g/day) also support the findings of
our pooled analysis; TG concentrations were significantly
lowered by 9–19% after 4–6 weeks of intervention with
PS-enriched (soy)milk or spread in subjects with baseline
TG concentrations[1.5 mmol/L [5–8]. For plant stanols as
well, significant decreases in TG concentrations were
shown in subjects with overt hypertriglyceridaemia [38].
The TG-lowering effect observed in our pooled analysis
seems robust. Heterogeneity analysis did not reveal sig-
nificant variability between studies. In addition, the sensi-
tivity analysis showed that removing the study with statin
users did not affect the outcome. Also, the use of only the
first phase of cross-over trials in the overall analysis did not
change the results. At last, the majority of studies included
in the pooled analysis were of good quality, and most
individual studies showed a tendency towards the same
direction in the form of non-significant TG reductions.
Our results indicate that the absolute (mmol/L) reductions
in TG achieved with PS intake are dependent of baseline TG
concentrations. A significant interaction on relative (%)
TG changes was not present. However, it cannot be fully
excluded that the current analysis may have been under-
powered to detect such an effect. Nevertheless, the present
results suggest that the impact of baseline TG is more pro-
nounced on absolute changes in TG concentrations than on
relative changes from baseline. By expressing TG changes
as % change from baseline, at least part of the variability in
PS effects due to inter-individual variations in baseline TG is
taken into account. Therefore, it appears preferable to
express the TG changes in relative terms when referring to
the mean effect in a population.
Our data fit well with the findings of two studies reporting
large control-adjusted TG reductions of 19–28% (corre-
sponding to 0.23 to *0.4 mmol/L) following the con-
sumption of 2–4 g/day PS/stanols in metabolic syndrome
subjects with baseline TG concentrations of 2.2–2.4 mmol/L
[10, 11]. We estimated, for our study population, a reduction
of 0.18 mmol/L in subjects with baseline TG concentrations
at the 75th percentile (1.9 mmol/L). If our pooled analysis
had comprised a larger proportion of subjects with higher
baseline TG concentrations and/or subjects with the meta-
bolic syndrome, it is likely that even larger TG reductions
would have been observed. Taken together, these data
suggest that PS/stanols would be particularly useful for a
dual benefit on both LDL-C and TG in subjects with both
lipid abnormalities.
Based on the significant reductions in large and medium
size VLDL particles observed in subjects with the meta-
bolic syndrome, Plat et al. [39] suggested that a reduced
hepatic VLDL1 secretion could be a mechanism involved
in the TG-lowering effect of plant stanols. The unaltered
CETP mass observed in their subjects coupled with
unchanged HDL-C concentrations [39] is consistent with
the absence of effect of PS on HDL-C observed in the
present study. Overall, these data suggest that the reduced
TG concentrations attributable to either PS or stanol con-
sumption may not be ascribed to a remodelling of TG-rich
lipoproteins via CETP activity.
The findings of the current pooled analysis are limited
by the fact that the randomised controlled trials included in
the analysis present only a selection of studies available in
the literature. Also because the included studies were all
industry-sponsored, selection bias might possibly be pres-
ent. However, all studies were planned and executed by
independent research groups and published in peer-
reviewed journals. Because we re-analysed individual
subject data of a large number of subjects (935 in total), we
believe that there was sufficient power to substantiate the
conclusions drawn and that adding more subject data from
other studies would not have changed the outcomes. In
addition, because most studies used PS doses within a
narrow range (between 1.6 and 2.5 g/day), this does not
allow drawing any conclusion on a possible dose–response
relationship for the TG lowering effect of PS.
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In the absence of intervention studies that directly
quantified the CHD risk reduction resulting from lowering
TG only, it is difficult to determine whether the additional
effect that a modest 6% TG reduction may have on CHD
risk is clinically relevant next to the average 10% LDL-C
reduction achievable with an intake of 2 g/day of PS.
Nevertheless, although not as strong as LDL-C, elevated
TG is increasingly being recognised as a possible risk
factor for CHD [12–14]. Additional research into the rel-
evance of TG lowering for CHD risk reduction, and into
interventions (e.g. diet and lifestyle interventions) that
beneficially impact TG, is therefore warranted.
In conclusion, foods enriched with PS modestly lower
TG concentrations, especially in those with high TG con-
centrations at baseline. This effect may add to the overall
benefit of using PS-enriched foods as part of therapeutic
lifestyle and diet changes for improving blood lipid
profiles.
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